20000630 73

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/47, 9/107

A1

(11) International Publication Number: **WO 99/61025**

(43) International Publication Date: 2 December 1999 (02.12.99)

(21) International Application Number: PCT/EP99/03623

(22) International Filing Date: 26 May 1999 (26.05.99)

(30) Priority Data:

9811200.6	26 May 1998 (26.05.98)	GB
9818105.0	19 August 1998 (19.08.98)	GB

(71) Applicant *(for all designated States except AT US)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH–4058 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS–ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A–1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: LANG, Steffen [DE/CH]; Predigerweg 1, CH–4153 Reinach (CH). LIECHTI, Kurt [CH/CH]; Bienenstrasse 6, CH–4104 Oberwil (CH).

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH–4002 Basel (CH).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

This Sheet Has Been Replaced



(54) Title: MICROEMULSION PRECONCENTRATES CONTAINING A PIPERIDINE SUBSTANCE P ANTAGONIST

(57) Abstract

Microemulsion comprising a piperidine, e.g. 1–acyl–piperidine Substance P Antagonist and its use in the treatment of CNS disorders, e.g. depression and social phobia, and respiratory diseases, e.g. asthma and chronic bronchitis.